Home › Macular Degeneration › Virginia › Lynchburg
Macular Degeneration clinical trials in Lynchburg, VA
5 studies for Macular Degeneration are looking for participants at sites in and around Lynchburg (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
RecruitingPhase 2/3
- Piedmont Eye Center (Site 054), Lynchburg
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RecruitingPhase 2/3
- Piedmont Eye Center, Lynchburg
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
- Piedmont Eye Center, Lynchburg
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RecruitingPhase 2
- Piedmont Eye Center, Lynchburg
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RecruitingPhase 3
- Piedmont Eye Center, Lynchburg
About Macular Degeneration
Macular degeneration, or age-related macular degeneration (AMD), causes vision loss in older adults. Learn about the types and what can help.
More about Macular Degeneration on MedlinePlus
Macular Degeneration trials in other cities
- Dallas, TX13 studies
- Erie, PA10 studies
- The Woodlands, TX9 studies
- Reno, NV8 studies
- Hagerstown, MD8 studies
- Sacramento, CA8 studies
- Cleveland, OH7 studies
- Fort Worth, TX7 studies
- Austin, TX7 studies
- Salt Lake City, UT7 studies
- Carmel, IN7 studies
- Houston, TX7 studies
Other studies in Lynchburg
- Breast Cancer4 studies
- Geographic Atrophy4 studies
- Non-Small Cell Lung Cancer4 studies
- Lung Cancer3 studies
- Crohn's Disease3 studies
- Atrial Fibrillation3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.